国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (4): 258-261.doi: 10.3760/cma.j.issn.1673422X.2016.04.005

• 论著 • 上一篇    下一篇

微波消融术联合索拉非尼治疗晚期肝细胞癌的临床研究

张亚非,盛立军,孙亚红,宋鹏远,任国华,安玉姬   

  1. 50031 济南，山东省医学科学院附属医院内五科（张亚非、盛立军、孙亚红、宋鹏远、任国华、安玉姬）；济南大学 山东省医学科学院医学与生命科学学院（张亚非）
  • 出版日期:2016-04-08 发布日期:2016-03-02
  • 通讯作者: 盛立军，Email: shenglijun328@126.com E-mail:shenglijun328@126.com

Clinical research of microwave ablation plus sorafenib in the treatment of advancedstage hepatocellular carcinoma

Zhang Yafei, Sheng Lijun, Sun Yahong, Song Pengyuan, Ren Guohua, An Yuji   

  1. Fifth Department of Internal Medicine, Affiliated Hospital of Shandong Academy of Medical Sciences; School of Medicine and Life Sciences, University of Ji′nan, Shandong Academy of Medical Sciences, Ji′nan 250031, China
  • Online:2016-04-08 Published:2016-03-02
  • Contact: Sheng Lijun E-mail:shenglijun328@126.com

PDF

997

被引次数

3

摘要： 目的比较微波消融术（MWA）联合索拉非尼与索拉非尼单药治疗晚期肝细胞癌(HCC)的临床疗效及不良反应。方法回顾性分析57例晚期原发性HCC患者的病历和随访资料，其中25例患者接受MWA联合索拉非尼治疗（联合组），32例患者接受索拉非尼单药治疗（单药组），观察终点为两组患者的治疗疗效、无进展生存时间(PFS)、总生存时间(OS)及不良反应。结果联合组和单药组客观缓解率分别为16.0%和3.1%，差异无统计学意义（χ2=1.521，P=0.217）。联合组的疾病控制率为80.0%，明显高于单药组的50.0%，差异有统计学意义（χ2=5.429,P=0.020）。联合组的中位PFS显著长于单药组（6.0个月∶3.2个月，χ2=7.675，P=0.006），而联合组与单药组的中位OS差异无统计学意义（11.5个月∶8.5个月，χ2=2.480，P=0.115）。联合组和单药组3～4级不良反应发生率分别为44.0%和34.4%，差异无统计学意义(χ2=0.549，P=0.459)。结论联合组与单药组比较虽OS无明显延长，但联合组PFS长于单药组，且没有增加严重不良反应发生风险。

关键词: 肝肿瘤, 微波, 索拉非尼

Abstract: ObjectiveTo compare the clinical effects and adverse effects of microwave ablation (MWA) with sorafenib and sorafenib monotherapy in the treatment of advancedstage hepatocellular carcinoma (HCC). MethodsMedical records and followup information of 57 patients with advancedstage HCC were retrospectively reviewed. 25 patients were treated with MWA combined with sorafenib (combined group), and 32 patients were treated with sorafenib monotherapy (monotherapy group). The end points were therapeutic effect, progressionfree survival (PFS), overall survival (OS) and adverse reactions. ResultsThe objective response rate in the combined group was similar to the monotherapy group (16.0% vs. 3.1%, χ2=1.521, P=0.217). The disease control rate in the combined group was significantly higher than that in the monotherapy group (80.0% vs. 50.0%, χ2=5.429, P=0.020). The median PFS in the combined group was longer than that in the monotherapy group (6.0 months vs. 3.2 months, χ2=7.675, P=0.006), but the median OS was similar (11.5 months vs. 8.5 months, χ2=2.480, P=0.115). The serious adverse reactions were similar between the two treatment groups (44.0% vs. 34.4%, χ2=0.549, P=0.459). ConclusionMWA plus sorafenib is superior to sorafenib alone with respect to PFS in patients with advancedstage HCC, although it may not improve OS, with no increased risk of serious adverse reactions.

Key words: Liver neoplasms, Microwaves, Sorafenib